Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $6.20 USD
Change Today -0.06 / -0.96%
Volume 246.7K
ECYT On Other Exchanges
Symbol
Exchange
NASDAQ GS
Berlin
As of 8:10 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

endocyte inc (ECYT) Key Developments

Endocyte, Inc. Announces Unaudited Earnings Results for the First Quarter Ended March 31, 2015

Endocyte, Inc. announced unaudited earnings results for the first quarter ended March 31, 2015. For the quarter, the company announced collaboration revenue of $12,000 compared to $17,269,000 for the same period a year ago. Loss from operations was $10,965,000 compared to $3,219,000 for the same period a year ago. Net loss was $10,870,000 compared to $3,141,000 for the same period a year ago. Net loss per share, basic and diluted was $0.26 compared to $0.09 for the same period a year ago.

Endocyte, Inc., Q1 2015 Earnings Call, May 07, 2015

Endocyte, Inc., Q1 2015 Earnings Call, May 07, 2015

Endocyte, Inc. Appoints P. David Mozley, M.D. as Vice President of Imaging

Endocyte, Inc. announced that P. David Mozley, M.D. has been appointed as vice president of imaging. Prior to joining Endocyte, he served as professor and chief of the Division of Nuclear Medicine at Weill Cornell Medical College and the New York Presbyterian Hospital/Weill Cornell Campus in Manhattan.

Endocyte, Inc., Annual General Meeting, May 14, 2015

Endocyte, Inc., Annual General Meeting, May 14, 2015., at 12:00 Eastern Daylight. Location: 600 East 96 Street. Agenda: To elect three directors to serve until the 2018 annual meeting of stockholders; to consider ratifying the appointment of Ernst & Young LLP as the company’s independent registered public accounting firm for 2015; and to transact such other business as may properly come before the meeting.

Endocyte, Inc. Announces Unaudited Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

Endocyte, Inc. announced unaudited earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported collaboration revenue of $12,000 compared to $17,274,000 a year ago. Loss from operations was $8,187,000 compared to $2,963,000 a year ago. Net loss was $8,081,000 compared to $2,902,000 a year ago. Basic and diluted loss per share was $0.19 compared to $0.08 a year ago. For the year, the company reported collaboration revenue of $70,353,000 compared to $64,871,000 a year ago. Income from operations was $5,026,000 compared to loss from operations of $18,342,000 a year ago. Net income was $5,459,000 compared to net loss of $18,032,000 a year ago. Basic and diluted earnings per share were $0.13 compared to basic and diluted loss per share of $0.50 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ECYT:US $6.20 USD -0.06

ECYT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ECYT.
View Industry Companies
 

Industry Analysis

ECYT

Industry Average

Valuation ECYT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.8x
Price/Book 1.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ENDOCYTE INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.